Chen et al [25] investigated the putative synergistic immunotherapeutic roles of LBP and IFNα2b against renal cell carcinoma (RCC) in vitro and in vivo, and the results suggested that the combination of LBP and IFNα2b is likely to be more effective in treating murine RCC compared with the less pronounced immunotherapeutic effects of administering IFN-α2b alone. The gene discussed is IFNA2; the disease is hereditary clear cell renal cell carcinoma.